Report |

DR-TB Drugs Under the Microscope, 2nd Edition

English (ENG) and Spanish (ES) versions available to download

Thumbnail
Photograph by Natalia Sergeeva

This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.

Also, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.

DR-TB Drugs Under the Microscope, 2nd Edition

/